Tokai Pharmaceuticals Announces Presentations On Galeterone At The AACR Annual Meeting 2016

BOSTON--(BUSINESS WIRE)--Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that two presentations on galeterone will be made during poster sessions held at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistance prostate cancer.

Back to news